BR112023001942A2 - Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento - Google Patents
Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complementoInfo
- Publication number
- BR112023001942A2 BR112023001942A2 BR112023001942A BR112023001942A BR112023001942A2 BR 112023001942 A2 BR112023001942 A2 BR 112023001942A2 BR 112023001942 A BR112023001942 A BR 112023001942A BR 112023001942 A BR112023001942 A BR 112023001942A BR 112023001942 A2 BR112023001942 A2 BR 112023001942A2
- Authority
- BR
- Brazil
- Prior art keywords
- fatigue
- complement
- inflammatory cytokines
- individual
- mediated disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5428—IL-10
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/224—Haemostasis or coagulation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/306—Chronic fatigue syndrome
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062243P | 2020-08-06 | 2020-08-06 | |
| PCT/US2021/044761 WO2022031978A1 (en) | 2020-08-06 | 2021-08-05 | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023001942A2 true BR112023001942A2 (pt) | 2023-02-28 |
Family
ID=77750323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023001942A BR112023001942A2 (pt) | 2020-08-06 | 2021-08-05 | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230357433A1 (https=) |
| EP (1) | EP4193153A1 (https=) |
| JP (1) | JP2023536904A (https=) |
| KR (1) | KR20230044312A (https=) |
| CN (1) | CN116724236A (https=) |
| AU (1) | AU2021320870A1 (https=) |
| BR (1) | BR112023001942A2 (https=) |
| CA (1) | CA3187866A1 (https=) |
| IL (1) | IL300376A (https=) |
| MX (1) | MX2023001492A (https=) |
| WO (1) | WO2022031978A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3722320A3 (en) | 2012-10-25 | 2020-12-30 | Bioverativ USA Inc. | Anti-complement c1s antibodies and uses thereof |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| CN110300520B (zh) | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| WO2022212645A1 (en) * | 2021-03-31 | 2022-10-06 | Bioverativ Usa Inc. | Reducing surgery-associated hemolysis in cold agglutinin disease patients |
| US20240117021A1 (en) * | 2022-06-15 | 2024-04-11 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| CA3260415A1 (en) * | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9206422D0 (en) | 1992-03-24 | 1992-05-06 | Bolt Sarah L | Antibody preparation |
| CA2118508A1 (en) | 1992-04-24 | 1993-11-11 | Elizabeth S. Ward | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| PL209392B1 (pl) | 1999-01-15 | 2011-08-31 | Genentech Inc | Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7083784B2 (en) | 2000-12-12 | 2006-08-01 | Medimmune, Inc. | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| DK2914291T3 (da) | 2012-11-02 | 2022-05-16 | Bioverativ Usa Inc | Anti-komplement-c1s-antistoffer og anvendelser deraf |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| CA2981321A1 (en) | 2015-04-06 | 2016-10-13 | True North Therapeutics, Inc. | Humanized anti-c1s antibodies and methods of use thereof |
| MX2017016835A (es) * | 2015-06-26 | 2018-08-01 | Bioverativ Usa Inc | Métodos de tratamiento de trastornos autoinmunitarios y aloinmunitarios. |
| US11464810B2 (en) * | 2016-08-25 | 2022-10-11 | California Institute Of Technology | Ascaroside treatment of eosinophilic esophagitis |
| CN110300520B (zh) * | 2016-10-12 | 2022-10-04 | 美国比奥维拉迪维股份有限公司 | 抗C1s抗体及其使用方法 |
| CR20190468A (es) | 2017-03-14 | 2019-12-17 | Bioverativ Usa Inc | Métodos para tratar enfermedades y trastornos mediados por completo |
| EP3774892A4 (en) * | 2018-04-13 | 2022-02-16 | Chugai Seiyaku Kabushiki Kaisha | ANTI-COMPLEMENT COMPONENT ANTIBODIES AND METHODS OF USE |
| JP7499760B2 (ja) * | 2018-11-02 | 2024-06-14 | アネクソン，インコーポレーテッド | 脳損傷を治療するための組成物及び方法 |
-
2021
- 2021-08-05 IL IL300376A patent/IL300376A/en unknown
- 2021-08-05 BR BR112023001942A patent/BR112023001942A2/pt unknown
- 2021-08-05 MX MX2023001492A patent/MX2023001492A/es unknown
- 2021-08-05 CN CN202180056699.1A patent/CN116724236A/zh active Pending
- 2021-08-05 KR KR1020237007908A patent/KR20230044312A/ko active Pending
- 2021-08-05 AU AU2021320870A patent/AU2021320870A1/en active Pending
- 2021-08-05 JP JP2023507563A patent/JP2023536904A/ja active Pending
- 2021-08-05 WO PCT/US2021/044761 patent/WO2022031978A1/en not_active Ceased
- 2021-08-05 EP EP21770091.3A patent/EP4193153A1/en active Pending
- 2021-08-05 CA CA3187866A patent/CA3187866A1/en active Pending
-
2023
- 2023-02-03 US US18/164,521 patent/US20230357433A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4193153A1 (en) | 2023-06-14 |
| KR20230044312A (ko) | 2023-04-03 |
| US20230357433A1 (en) | 2023-11-09 |
| WO2022031978A1 (en) | 2022-02-10 |
| IL300376A (en) | 2023-04-01 |
| CA3187866A1 (en) | 2022-02-10 |
| MX2023001492A (es) | 2023-03-08 |
| AU2021320870A1 (en) | 2023-04-06 |
| CN116724236A (zh) | 2023-09-08 |
| JP2023536904A (ja) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023001942A2 (pt) | Citocinas inflamatórias e fadiga em indivíduo com doença mediada por complemento | |
| Ochoa et al. | Positive psychotherapy for distressed cancer survivors: Posttraumatic growth facilitation reduces posttraumatic stress | |
| BR112018069297A2 (pt) | composição, e, métodos para induzir uma resposta imune e para tratar um indivíduo que foi diagnosticado com uma doença ou distúrbio | |
| DOP2022000233A (es) | Anticuerpos de unión a cd3 | |
| BR112022002831A2 (pt) | Formulações anti-c5 de alta concentração | |
| BR112016016525A2 (pt) | Método para indução de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+ em um indivíduo, método para melhorar uma condição em um indivíduo, e método para a produção de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+ | |
| BR112015024926A2 (pt) | composições, artigo de fabricação, métodos para tratar um paciente com câncer, para avaliar uma composição, para avaliar a atividade biológica, para produzir uma composição e para avaliar a fragmentação de uma composição e variante de pertuzumabe | |
| BR112016010166A2 (pt) | métodos para usar interleucina-10 para tratar doenças e distúrbios | |
| BR112014007687A8 (pt) | Composiçâo farmacêutica de anticorpos para eliminação de antígenos no plasma | |
| BR112016029226A2 (pt) | métodos e composições para o tratamento de úlceras | |
| BR112022001148A2 (pt) | Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto | |
| BRPI1014544B8 (pt) | anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo | |
| BR112013026976A2 (pt) | alfa glucosidade ácida modificada com processamento acelerado | |
| BR112019027133B8 (pt) | Uso de uma célula imune modificada deficiente para suv39h1 | |
| BR112022005678A2 (pt) | Métodos e composições para o tratamento da retinopatia diabética | |
| BR112021015222A2 (pt) | Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1 | |
| CL2021002483A1 (es) | Compuestos y composiciones como moduladores de la señalización tlr | |
| BR112019011365A2 (pt) | métodos para tratar câncer | |
| BR112012026007A2 (pt) | método e composições para a inibição de células treg, bem como uso de células th1 alogênicas e uma fonte de antígenos | |
| Webb et al. | Non-binary gender identities | |
| PE20141826A1 (es) | Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones | |
| Geddes | Puzzle over viral load | |
| Park | The effects of shift work and hours of sleep on metabolic syndrome in Korean workers | |
| BR112023026559A2 (pt) | Formas cristalinas de trofinetida | |
| BR112017020783A8 (pt) | Tratamento de dor |